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Expression of a novel versican variant
in dorsal root ganglia from spared
nerve injury rats
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Abstract
The size and modular structure of versican and its gene suggest the existence of multiple splice variants. We have identified,
cloned, and sequenced a previously unknown exon located within the noncoding gene sequence downstream of exon 8.
This exon, which we have named exon 8b, specifies two stop-codons. mRNAs of the versican gene with exon 8b are
predicted to be constitutively degraded by nonsense-mediated RNA decay. Here, we tested the hypothesis that these
transcripts become expressed in a model of neuropathic pain.
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Introduction
The extracellular matrix molecule versican is a member
of the lectican gene family; chondroitin sulfate carrying
proteoglycans with an immunoglobulin-like hyaluronan-
binding domain at their N-terminus and a C-type
lectin-like binding motif at their C-terminus.1,2 Five
splice variants of versican (V0, V1, V2, V3, and V4)
have been identified so far and the existence of addition-
al variants has been proposed.3 All five splice variants
have identical N- and C-termini but vary with respect to
the size of their protein backbone and the number of
attached chondroitin sulfate chains.4–8
The versican gene (Vcan; Synonym: CSPG2), which is
located on chromosome 2 in the rat genome,9 and on
chromosome 5 in humans,10 consists of 15 exons that
encompass almost 100 kilo bases (kb) of continuous
DNA. V0, versican’s largest splice variant, is generated
by the transcription and translation of its whole set of
protein encoding exons. The other four variants are
products of alternative splicing of exon 7 and (or
within) exon 8, which encode versican’s glycosaminogly-
can (GAG) attachment domains, GAG a and GAG
b.8,11 Therefore, V0 carries both GAG attachment
domains, GAG a and GAG b, V1 only GAG b, V2
only GAG a, and V3 no GAG domain, whereas V4
carries only a shortened GAG b-domain.2,8 (Figure 1).
We have previously demonstrated that the versican
variants V0 to V3 are transcribed by sensory neurons,
in dorsal root ganglia (DRG).12 We also demonstrated
that the “enigmatic” IB4-reactivity of nonpeptidergic
C-fiber nociceptors can be traced back to the covalent
modification of Vcan V2 with a-D-galactopyranose res-
idues.12,13 Here, we took a closer look at versican’s gene
structure. Given the spatial dimensions of the Vcan
gene and the modular structure of its corresponding
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gene products we hypothesized the existence of addition-
al splice variants.
By searching expressed sequence tag (EST) databases
for transcribed sequences that could be mapped to the
genomic region of the human versican gene, we identified
one clone (BI818462), which contains a cDNA sequence
that could not be completely assigned to any of the known
versican exons. Its nucleotide sequence is well conserved in
the rat. Using oligonucleotide primers specific for the
amplification of transcripts of the Vcan gene carrying
this splice insertion we were able to clone 2 overlapping
cDNA-fragments from RNA extracts of rat nervous
tissue. The derived sequence of both clones provides evi-
dence for the existence of a previously unknown exon. The
new exon contains two stop codons. Spliced transcripts of
the versican gene that include this exon should, therefore,
be degraded by nonsense-mediated mRNA decay under
normal circumstances.14 We explored the hypothesis that
mRNAs containing this exon are being translated into a
C-terminal truncated variant of versican under conditions
of extreme cellular stress in the peripheral nervous system.
Material and methods
Animals
Experiments were performed on adult male Sprague
Dawley rats (Crl:CD; 280–350 g, approximately
8–12 weeks old) because the pathophysiological
changes associated with spared nerve injury demon-
strate greater variability in female rats.15 Rats were
obtained from Charles River Laboratories (Hollister,
CA, USA) and housed in an AAALAC International
accredited animal facility, the Laboratory Animal Resource
Center of the University of California San Francisco, under
a 12-hour light/dark cycle, with water and food available ad
libitum. Animal care and use conformed to NIH guidelines.
The University of California, San Francisco Institutional
Animal Care and Use Committee approved all experimen-
tal protocols. Concerted effort was made to reduce the suf-
fering and number of animals used.
Cloning of exon 8b
Total RNA from rat brain and spinal cord was extracted
using Trizol reagent (Invitrogen, Carlsbad, CA, USA)
with the PureLinkTM RNA mini kit (Life
Technologies, Grand Island, NY, USA), according to
the manufacturer’s instructions. The amount of RNA
was quantified with a UV-spectrophotometer, and
cDNA preparation carried out with 1 mg of total
RNA/sample and the superscript III platinum one-step
RT-PCR system (Life Technologies). The PCR primers
(Invitrogen) used for the detection and amplification of
the different versican fragments were, according to the
National Center for Biotechnology Information
Figure 1. Schematic representation of the genomic structure of the versican gene, including exon structure of the five known splice
variants. Its 15 exons are represented as colored rectangles. Exons 1 to 6 and 9 to 15 are represented by red rectangles. Exons 7 and 8 are
represented by green rectangles. The part of exon 8 that is expressed in versican V4 is represented by a blue rectangle. The black line
between the exons in the top illustration represents non-coding intervening sequences. The black lines that connect the exons in the
representation of the different splice variants illustrate the splicing process through which the different versican variants are generated.
Note that the start-codon for versican biosynthesis is located within exon 2. GAG: glycosaminoglycan.
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database entry NM_001170558, as follows: Vcan_exon
4_for¼ 50-GCG ACC AGC AGA TAC ACT CT-30,
Vcan_exon6_rev¼ 50-ATC CGA CAG CCA GCC
GTA AT-30 [size of the amplification product¼ 435 bp,
number of PCR cycles: 30]; Vcan_exon8_for¼ 50-GGG
TTG AGA CAA GTA TGG TAC CT-30, Vcan_
exon8b_rev¼ 50-GCA CTG ACG TTT CTT CTG
CTA CA-30 [size of the amplification product¼ 372 bp,
number of PCR cycles: 40]; Vcan_exon8b_for¼ 50-TGT
AGC AGA AGA AAC GTC AGT GC-30, and, Vcan_
exon11_rev¼ 50-CAT GTA CGG CGA TGA GCA
AAG TA-30 [size of the amplification product¼ 360 bp,
number of PCR cycles: 40].
PCR products inserted into the pCR4TM-TOPO vector
(Invitrogen) were used to transform chemically competent
Escherichia coli cells (TOP10; Invitrogen). Only clones
that were verified by restriction analysis were selected
for DNA sequencing (GenScript, New Jersey, NJ, USA).
Spared nerve injury
The spared nerve injury model, a well-established surgical
model of neuropathic pain, was performed as previously
described.16 Briefly, rats were anesthetized with 2.5% iso-
flurane (Henry Schein Animal Health, Dublin, OH, USA)
in oxygen and s.c. injected with 2mg/kg meloxicam
(Metacam, Boehringer Ingelheim Vetmedica, St. Joseph,
MO, USA). Rat corneas were protected with ophthalmic
ointment (Artificial Tears, Rugby, Livonia, MI, USA)
during the surgical procedure. The surgical site was infil-
trated with 0.1ml of 0.25% bupivacaine (Marcaine,
Hospira, Lake Forest, IL, USA) immediately before inci-
sion. The skin on the lateral surface of the right thigh was
incised and a dissection made through the biceps femoris
muscle exposing the sciatic nerve and its three terminal
branches. The tibial and common peroneal nerve branches
were tightly ligated with 5–0 silk (Surgical Suture U.S.P.,
Henry Schein) and sectioned 1 mm distal to the ligation.
A 2 mm segment of the distal nerve stump was then
excised. Care was taken to avoid any contact, stretching,
or damage of the intact sural nerve. Sham surgery con-
sisted in the exposure of the sciatic nerve and its branches
without any lesion. Muscle was sutured with 5–0 silk and
skin closed with 5–0 nylon (Surgical Suture U.S.P., Henry
Schein). Rats recovered from anesthesia in an individual
cage with a heat source and were transferred to standard
housing cages when fully awake. Once ambulatory, rats
received a daily s.c. injection of meloxicam for the first
twodays after surgery. Rats were allowed to recover for
one week before tissue harvesting.
Tissue harvesting and protein extraction
On post-surgery day 7, rats subjected to SNI or sham-
surgery were euthanized by exsanguination while under
isoflurane anesthesia. Ipsilateral L4 to L6 DRG were
surgically removed, snap frozen on dry ice, and stored
at 80C until further processing. DRG were trans-
ferred into homogenization buffer [150mM NaCl,
50mM Tris-HCl pH 7.4, 2mM EDTA, 2% sodium
dodecylsulfate (SDS)] supplemented with a complete
protease inhibitor cocktail (Roche Diagnostics Corp.,
Indianapolis, IN, USA) and manually homogenized
with a plastic pestle. Proteins were solubilized by incu-
bating the homogenate for 2 h at 25C in an Eppendorf
Thermomixer at 1400 r/min and then extracted by a
15min centrifugation at 14,000 r/min, in an Eppendorf
tabletop centrifuge. Protein concentration of the samples
was determined using the micro bicinchoninic acid assay
(BCA) protein assay kit (Pierce, Rockford, IL, USA)
with bovine serum albumin (BSA) as a standard.
SDS-PAGE and Western blot analysis of
eIF2a(PO4)
2-immunoreactivity
40 mg of protein per sample was mixed with 4 sample
buffer [62.5mM Tris-HCl pH 6.8, 3% SDS, 10% glyc-
erol, 0.025% bromphenol blue], denatured by shaking
for 10min at 500 r/min at 90C in an Eppendorf
Thermomixer and electrophoresed on a 4%–15% pre-
cast polyacrylamide gel (Biorad, Hercules, CA, USA)
in 25mM Tris buffer containing 192mM glycine, and
0.1% SDS. Proteins were transferred onto a nitrocellu-
lose (NC) membrane using the semidry method (transfer
time 2 h at 1.5mA*cm2 with 47.9mM Tris, 38.9mM
glycine, 0.038% SDS and 20% (v/v) methanol).
The blotting membrane was saturated by shaking in
Tris-buffered saline pH 7.4 containing 5% BSA and
0.1% Tween 20 (antibody dilution buffer) for 1 h at
room temperature (RT). The blot was probed with a
rabbit anti-eIF2a antibody (Cell signaling technology,
catalog #9722S; 1:500 in antibody dilution buffer) at
4C overnight, rinsed with TBST (three times at RT,
15min each) and probed with a donkey anti-rabbit
horseradish peroxidase conjugated antibody (GE health-
care, catalog#NA934V; 1:2500 in antibody dilution
buffer) for 2 h at RT. The Western blot was rinsed
with TBST (three times at RT, 15min each) and the
eIF2a immunoreactivity visualized with the enhanced
chemiluminescence (ECL) detection kit (Pierce).
The Western blot was stripped by a 1 h incubation at
RT with 2% SDS, 10mM b-mercaptoethanol in
62.5mM Tris-HCl pH 6.8, and washed extensively
with TBST. The blotting membrane was saturated with
TBST containing 5% BSA and probed with the rabbit
anti-eIF2aPO4
2 antibody (Cell signaling technology,
catalog #9722S; 1:500 in antibody dilution buffer) over-
night at 4C. The blot was rinsed with TBST (three times
at RT, 15min each), probed with a biotinylated anti-
rabbit antibody (Jackson Immunoresearch, catalog#
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111–065-003; 1:2500 in antibody dilution buffer) for 2 h
at RT, rinsed with TBST (three times at RT, 15min
each), probed with streptavidin horseradish peroxidase
(Sigma-Aldrich, catalog# S2438; 1:5000 in antibody
dilution buffer) for 1 h at RT and rinsed with TBST
(three times at RT, 15min each). eIF2aPO4
2 immuno-
reactivity was visualized with the ECL detection kit
(Pierce). Results were analyzed by computer-assisted
densitometry and levels of eIF2aPO4
2 immunoreactiv-
ity were normalized with respect to the eIF2a immuno-
reactivity in each sample.
Deglycosylation and Western blot analysis of Vcan
immunoreactivity
1.5mg of protein in homogenization buffer from DRG
of SNI rats was transferred into 10K cutoff centrifugal
filter devices (Millipore, Burlington, MA, USA) and the
buffer replaced through stepwise and repeated centrifu-
gation at 10,000 r/min and the addition of bridging
buffer [phosphate buffered saline pH 7.4 containing
1% Triton X-100 and 1% sodium deoxycholate and
supplemented with 2x complete protease inhibitor cock-
tail (Roche)]. The proteins in bridging buffer were fur-
ther replaced through stepwise and repeated
centrifugation at 10000 r/min and the addition of degly-
cosylation buffer [0.1M NaxHxPO4-buffer pH 5.5 con-
taining 0.05M NaCl, 1% Triton X-100 and 1%
Tween20 and supplemented with 2 complete protease
inhibitor cocktail (Roche)]. The proteins in deglycosylation
buffer were transferred into an Eppendorf tube, mixed
with 50U hyaluronidase (Sigma Aldrich, Saint Louis,
MO, USA), and incubated for 2h at 37C in an
Eppendorf Thermomixer. The proteins were transferred
into a 10 k cutoff centrifugation filter device and the degly-
cosylation buffer with homogenization buffer exchanged
as described earlier. The protein concentration of the
sample was determined using the BCA protein assay kit
(Pierce) with BSA as the standard. Sixtymicrograms of
protein per lane were electrophoresed onto a 4%–15%
precast polyacrylamide gel and electro-blotted onto NC
membrane afterwards. The membrane was stained with
Ponceau S (0.1% Ponceau S in 5%(v/v) acetic acid) and,
using a scalpel, the lanes were separated from each other
by cutting the membrane into strips. The strips were trans-
ferred into a stripe box and blocked with blocking
buffer for 1h at RT. The strips were then probed with
the different Vcan antibodies [mouse monoclonal 12C5
(Developmental Studies Hybridoma Bank, University of
Iowa, Iowa City, IA); rabbit polyclonal anti-GAGa
(Millipore, catalog#AB1032), rabbit polyclonal anti-
GAGb (Millipore, catalog#ABT1370), mouse monoclonal
anti-Cterm. (Millipore, catalog#MABT161); all 1:500 in
antibody dilution buffer] at 4C overnight, rinsed with
TBST (three times, 15min each) and probed with the
respective horseradish peroxidase conjugated secondary
antibodies [anti-rabbit horseradish peroxidase (GE health-
care, catalog#NA934V), anti-mouse horseradish peroxi-
dase (Pierce, catalog#1858413); 1:2500 in antibody
dilution buffer] for 2 h at RT. The strips were rinsed in
TBST (three times, 15min each) and the Vcan immunor-
eactivities visualized with the ECL detection kit (Pierce).
Results
The EST, 603032745F1 is part of a V0/V1-based
splice variant in rat nervous tissue
The human EST is part of a clone (GenBank entry:
BI818462) that comprises 836 nucleotides. The nucleo-
tide sequence of this clone can be matched with sequen-
ces of the 30-end of exon 8, the unknown sequence
insertion and nucleotide sequences of exons 9, 10, and
11. The sequence of this EST/clone suggests that addi-
tional splice variants of the versican gene exist.
To determine whether this insertion represents an addi-
tional exon, several reverse transcriptase polymerase chain
reactions (RT-PCRs) were performed. Using primers locat-
ed within exon 8 and the unknown sequence insertion, we
amplified a 372bp cDNA-fragment of RNA extracts from
rat brain and spinal cord (Figure 2(a)). The resulting
PCR product from rat brain was inserted into the
pCR4TM-TOPO vector and amplified by propagation of
E. coli cells into which the vector had been transformed.
Several clones were checked by restriction analysis for the
presence of the insert (data not shown) before one
“positive” clone was selected for DNA sequencing.
Another RT-PCR was performed to define the 30 end
of the putative new exon. Using primers located within
the putative splice insertion and exon 11, we amplified a
360 bp cDNA-fragment from RNA of rat brain and
spinal cord (Figure 2(a)). The resulting PCR product
from rat brain was inserted into the pCR4TM-TOPO
vector and amplified by propagation in E. coli cells.
Several clones were checked by restriction analysis, for
the presence of the insert (data not shown), before one
“positive” clone was selected for DNA sequencing.
From the combination of the two cDNA sequences, one
can conclude that the splice insertion represents an addi-
tional exon within the Vcan gene. This exon—that we have
named exon 8b, because it is located downstream of exon
8, which encodes versican’s GAG b domain—is made of
102 nucleotides or 33 codons (Figure 2(b)), of which 31
specify amino acids and 2 stop signals (Figure 2(c)).
A C-terminal truncated versican variant can be detected
in DRG extracts from spared nerve injury rats
We have previously demonstrated that versican can bind
glial-cell line derived neurotrophic factor (GDNF) and
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MCP-1 at sensory terminals,17,18 although the precise
details of its molecular interaction with both molecules
are not yet clear. GDNF and MCP-1 are of particular
importance for sensory neurons in the event of nerve
injury as GDNF promotes the survival of IB4-binding,
nonpeptidergic C-fiber nociceptors,19–21 while MCP-1
attracts CCR2 expressing monocytes/macrophages to
the site of injury.22,23 To analyze if the novel versican
Figure 2. The EST 603032745F1/exon 8b is part of a V0- and/or V1-based mRNA. (a) 2 RT-PCRs were performed to define the spatial
dimensions of exon 8b; a RT-PCR with primers located within exon 8 and exon 8b amplified a 372bp DNA-fragment (lane 2), and a RT-PCR
with primers located within exon 8b and exon 11 amplified a 360bp DNA-fragment (lane 3). A control PCR with primers located within
exons 4 and 6 [size¼ 435bp]—which should detect all currently known versican splice variants12—was performed to verify the quality of
the RNA/cDNA preparation (lane 1). (b) Genomic context of exon 8b. Coding sequences (exons) are shown in bold letters. Non-coding,
intervening sequences (introns) are shown in plain letters. Exon 8b is highlighted in blue letters. The primer sequences that were used for
the amplification of cDNA-fragments including exon 8 are underlined; the top two primers were used to define the 50-end of exon 8b, the
bottom two primers were used to define its 30-end. Of note, the two primers located within exon 8b are complementary to each other
and of reverse orientation. (c) C-terminal amino acid sequence of the corresponding versican splice variant V5 (and a hypothetical variant
V6). Two stop-codons (red asterisks) within the reading frame of exon 8b would terminate protein translation of the corresponding
mRNA transcript downstream of exon 8, versicans GAGb domain.
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variant could also be transcribed in the peripheral ner-
vous system, we performed a PCR on RNA extracts of
DRG from rats subjected to the spared nerve injury
(SNI) model for neuropathic pain.16 As shown in
Figure 3(a), cDNA-fragments of the novel splice variant
could be amplified within RNA extracts of SNI but not
sham-operated rats.
mRNAs of the Vcan gene with exon 8b should be
degraded under normal circumstances.14 However,
axotomized neurons are experiencing extreme stress
Figure 3. A novel Vcan variant is expressed in SNI rats. (a) A novel Vcan variant is transcribed in SNI but not sham control rats. PCRs on
cDNA from rat DRG demonstrates that the new Vcan variant is also transcribed in spared nerve injury rats but that it is absent in sham-
operated rats. 1: Vcan_exon4_for and Vcan_exon6_rev¼ 435bp; 2: Vcan_exon8_for and Vcan_exon8b_rev¼ 372bp; 3: Vcan_exon8b_for
and Vcan_exon11_rev¼ 360bp. (b) ISR is activated in SNI rats. Analyzing the post-translational modification of eIF2a by Western blotting
demonstrates a significant increase of eIF2aPO4
2 in DRG extracts from rats submitted to SNI compared to sham-surgery rats
[eIF2aPO4
2 immunoractivity in SNI¼ 126 12 arbitrary units; eIF2aPO42 immunoractivity in sham controls¼ 98 10 arbitrary units;
normalized to the reference protein eIF2a; P<0.05 (unpaired student’s t-test), a 28.4 15.8% increase in the eIF2aPO42 immunoreac-
tivity, N¼9]. Note that the calculated molecular weight of eIF2a PO42 is 36 kDa (according to the UniProtKB database entry P68101).
*P<0.05. (c) SNI rats express a C-terminally truncated Vcan variant. DRG extracts from SNI rats were analyzed by Western blotting using
a set of four different antibodies, each of which is directed against one of versican’s four major structural and functional domains. Rat V2 is
made of 1601 amino acids with a calculated molecular weight of 176 kDa.62 The discrepancy between its calculated and apparent
molecular weight on the Western blot can be explained by its highly acidic character, which interferes with micelle formation during gel
electrophoresis.63,64 The Vcan variant above V2 is composed of Vcan’s N-terminus and only the GAGb domain. It’s domain composition
and apparent molecular weight suggests that it is the C-terminal truncated Vcan variant predicted by the translation of V1-derived mRNAs
carrying exon 8b.
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as they struggle for survival.24 Cells respond to stress
with the integrated stress response (ISR), a genetic
program that targets the production of proteins that
protects the cell from harm.25 The ISR is often asso-
ciated with the inhibition of nonsense-mediated RNA
decay (NMD) given that the translation of a number
of transcripts for stress-related proteins are controlled
by NMD.26–28 Based on these findings, we analyzed if
the novel splice variant could also become expressed
in DRG from rats submitted to spared nerve injury.
First, we analyzed whether the phosphorylation of
eIF2a, a molecular marker for the ISR, could be
enhanced in SNI rats. Proteins extracted from DRG of
SNI or sham-operated rats were analyzed by Western
blotting. As shown in Figure 3(b), a comparison of the
eIF2aPO4
2 immunoreactivity between SNI and sham-
operated rats demonstrates a 28.4 15.8% increase
within protein extracts from SNI rats. We then analyzed
whether the novel splice variant is expressed in SNI rats.
Protein extracts from the DRG of SNI rats were degly-
cosylated, separated by gel electrophoresis, and analyzed
by Western blotting, using a set of four different anti-
bodies, each of which is specific to one of versican’s four
major functional domains. As shown in Figure 3(c), two
different versican variants could be detected. The lower
one, with an apparent molecular weight of >250 kDa, is
composed of versican’s N-terminus, its GAGa domain,
and its C-terminus and most likely represents versican
V2.12,13The second variant above V2 is comprised only
of the N-terminus and the GAGb domain and thus most
likely represents a C-terminal truncated version of versi-
can V1 (see Figures 1 and 4).
Discussion
We hypothesized that more than the five previously
reported versican splice variants exist (see Figure 1).
This hypothesis is based on the idea that the Vcan
gene comprises 15 exons and that most of these exons
encode self-contained structural and functional motifs
that could—theoretically—be assembled to many more
protein variants.1,11,29
Using the genomic sequence of human versican and
the algorithm blastn at the National Library of Medicine
Website we searched EST databases for cDNA sequen-
ces that are derived from the versican gene. We found a
clone whose nucleotide sequence carries an uncharacter-
ized splice insertion. Its nucleotide sequence could be
matched with an intronic sequence downstream of
exon 8 within the versican gene. The sequence of this
splice insertion is well conserved in the rat.
Using RNA extracts from rat central nervous system
(CNS) and PCR primers specific for the amplification of
transcribed sequences of the versican gene that include
this splice insertion, we generated two cDNA clones with
overlapping oligonucleotide sequences. From the combi-
nation of these cDNA sequences, one can conclude that
this splice insertion must represent an additional exon
with 102 nucleotides (see Figure 2(b)). The exact position
of this exon—for which we have chosen the name
Figure 4. Schematic representation of the potential structure of the novel versican variant V5 and its structural differences from two of
the “classic” splice variants, V0 and V3. Thick black lines represent the protein backbone. Thin blue lines represent the chondroitin sulfate
side chains, which are attached to versican’s GAG domains, and the thick blue line represents hyaluronan. Versican V0 is comprised of
three distinct structural domains, a hyaluronan-binding domain at its N-terminus, two GAG domains in the middle portion of the protein,
and a selectin-like domain at its C-terminus. V3 lacks both GAG domains and therefore comprises only the N-terminal hyaluronan-binding
domain and the C-terminal selectin-like domain. V5 lacks the C-terminal selectin-like domain and therefore would only be comprised of
the N-terminal hyaluronan-binding domain and the GAGb domain.
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8b because it is located downstream of exon 8, which
encodes versican’s GAG b domain—within the linear
sequence of the Vcan gene, according to the NIH data-
base entry NC_005101, is 64107–64209.
Exon 8b is framed by classical splice sites: the AG di-
ribonucleotide toward its 50-end represents the splice
acceptor site of the preceding intron and the GU di-
ribonucleotide toward the 30 end represents the splice
donor site of the subsequent intron.30,31 (Figure 2(b)).
Two additional consensus splice motifs required for the
excision of the intronic sequence that lies between exons
8 and 8b, the branch site (consensus sequence YURAC,
with Y¼ C or U and R¼ A or G; IUPAC nucleic acid
notation) and the polypyrimidine tract (pyrimidine-rich
stretch of 15–20 ribonucleotides),31,32 can be found 32 to
28 and 29 to 9 nucleotides upstream of exon 8b, respec-
tively (Figure 2(b)).
Exon 8b specifies two stop-codons (Figure 2(b)
and (c)). One could therefore predict that transcripts of
the Vcan gene with exon 8b are subjected to NMD, an
intrinsic quality control mechanism of eukaryotic cells
that stimulates the degradation of spliced mRNAs with a
premature termination codon (PTC).14 According to the
exon-junction complex activation model, the most
common model for NMD, does each additional stop-
codon upstream of the regular termination codon in
the open reading frame of a spliced mRNA, induce
NMD if it lies more than 50–55 nucleotides in front of
an exon–exon junction.33–35 Given that this so-called 50–
55 nucleotide rule applies to transcripts of the Vcan gene
with exon 8b we did not analyze whether the novel splice
variant is expressed in the CNS. We did, however,
analyze whether the novel versican variant could be
transcribed in the peripheral nervous system of neuro-
pathic rats. The idea for this experiment was based on
the finding that traumatized sensory neurons undergo
a phenotype switch; many of the molecules such as
danger associated molecular pattern molecules, cyto-
kines, growth factors, and stress hormones that are
released by injured cells and tissue, including glial
cells, leukocytes, and the hypothalamic-pituitary-
adrenal gland axis, stimulate the transcription of
genes that support the survival and recovery of the
damaged neurons.21,36–39
Following the detection of mRNAs of the novel var-
iant in the DRGs of SNI rats (Figure 3(a)), we analyzed
whether the transcribed sequences are also being trans-
lated into protein. The idea for this experiment was
based on the finding that (a) sensory neurons react to
mechanical injury,40 inflammation,41 and toxic insults42
with the integrated stress response (ISR), a genetic pro-
gram aiming to limit and reverse damage to cellular
components and (b) that the ISR is often associated
with the inhibition of NMD because some of the pro-
teins manufactured by the cell in response to stress such
as ATF-3 and ATF-4 are regulated by it.26–28 Our results
demonstrate that the eIF2a-PO4
2 immunoreactivity, a
molecular marker for the ISR, is increased in DRGs of
SNI rats (Figure 3(b)). eIF2a, one of three subunits of
eIF2, is a eukaryotic translation factor essential for
the initiation of CAP-dependent protein synthesis.43
The phosphorylation of eIF2a by stress-related protein
kinases is known to cause a drastic decrease in global
protein translation and, at the same time, leading to the
production of proteins that help the cell to limit
and reverse any damage that is caused by potential
stressors such as mechanical injury or reactive oxygen
species.43–45
The detection of a C-terminal truncated Vcan variant
in DRG of SNI rats (Figure 3(c)) suggests that NMD is
inhibited in axotomized sensory neurons. It is likely that
the inhibition of NMD in injured neurons is a conse-
quence of ER stress and the activation of the “classical”
PERK! eIF2a-PO42 ! ATF4! ATF3 signaling cas-
cade,46–49 a hypothesis also supported by the fact that
ATF3 and ATF4 are widely known to be up-regulated in
injured sensory neurons.47,50,51
The translation of mRNAs of the versican gene that
carry exon 8b could theoretically lead to the production
of two different C-terminal truncated variants: a V0-
derived variant that contains both GAG domains and
a V1-derived variant that contains the GAGb domain
only (see Figures 1 and 4). While our Western blot
results only provide evidence for the existence of the
V1 based variant (Figure 3(c)), this doesn’t rule out the
existence of the V0-based variant. Taking into account
the nomenclature of the previously characterized splice
variants,2,52 we propose to include the new versican var-
iant as V5 into the literature.
One would think that injured cells and tissues strug-
gling for survival express primarily genes that are essen-
tial for survival and recovery. How does the new
versican variant V5 fit into this category? By binding
and activating MCP-1 versican’s GAG side chains
could help to establish the chemotactic gradient that
attracts CCR2 expressing leukocytes,18 which, in turn,
will clear the injury site of dead cells and cellular
debris.22,23 Versican’s GAG chains could also provide
ample attachment sites for cell surface receptors such
as CD44, b1-integrin, and TLR 2/6 and 4 on glial cells
and leukocytes that help to restore tissue homeostasis
after injury.52,53 The electron-rich GAG side chains are
also known to: (a) protect cells against oxidative
stress,54,55, a major contributor to neuropathic pain
after nerve injury,56–60 and (b) bind GDNF,17 a survival
factor for traumatized IB4(þ), nonpeptidergic C-fiber
nociceptors.19 And finally, versican could initiate neuro-
nal regeneration by stimulating neurite outgrowth/
axonal regeneration.61 Interestingly, this property
seems to depend solely on versican’s GAG b domain
8 Molecular Pain
and the interaction of its GAG chains with b1-integrins
at the surface of regenerating neuronal processes.61
Taken together, we have confirmed the existence of a
new exon within the genomic sequence of the versican
gene and demonstrated that a novel versican splice
variant, comprised only of the immunoglobulin-like hya-
luronate binding N-terminus and a C-terminal GAG b
domain, is expressed in DRG under neuropathic condi-
tions. Our results suggest that the novel versican variant
V5 is a potential survival factor for injured senso-
ry neurons.
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